Given Altitrade Partners deep research I hope they/you are right. My personal preference, as well as my families, would be to see progress being made and a private buyout. This would be so much less complicated for everyone.
I wonder if Altitrade Partners has done a valuation recently. It has been a while. Has the market for Generx changed? Any other therapies catching up?
I'd also like to understand what the situation with Nostrum is at this time. Why did they take such a large interest in CRXM only to have Generx sit on a shelf?
News 
Market Data 
Discover 
